US2025042587A1PendingUtilityA1

Topical formulations and methods for bioactive & bioavailable naringenin for treating skin conditions

37
Assignee: PROTOCOL LAB LLCPriority: May 22, 2020Filed: Oct 21, 2024Published: Feb 6, 2025
Est. expiryMay 22, 2040(~13.8 yrs left)· nominal 20-yr term from priority
Inventors:Tyler Gaul
B65B 57/00B65B 1/04B65B 55/027B65B 31/025
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating a skin condition in a human patient. The method includes applying, to one or more affected areas of the human patient's skin, a naringenin formulation having an amount of naringenin effective to reduce or inhibit inflammatory processes.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating a skin condition in a human patient, the method comprising:
 applying, to one or more affected areas of the human patient's skin, a naringenin formulation having an amount of naringenin effective to reduce or inhibit inflammatory processes.   
     
     
         2 . The method of  claim 1 , wherein the naringenin formulation is applied as an adjunct therapy to a topical or an oral corticosteroid. 
     
     
         3 . The method of  claim 1 , wherein the naringenin formulation is further applied as an adjunct therapy to a topical or an oral antibiotic. 
     
     
         4 . The method of  claim 1 , wherein the naringenin formulation is applied to the one or more affected areas from  1  to about  10  times daily. 
     
     
         5 . The method of  claim 4 , wherein the naringenin formulation is applied to affected areas from  1  to about  5  times daily. 
     
     
         6 . The method of  claim 1 , wherein the naringenin formulation further comprises naringin. 
     
     
         7 . The method of  claim 1 , wherein the naringenin formulation does not include naringin. 
     
     
         8 . The method of  claim 1 , wherein the naringenin formulation is a water-based naringenin solution. 
     
     
         9 . The method of  claim 1 , wherein the skin condition is one or more of Rosacea, Ichthyosis, Actinic Keratosis, dermatitis, pruritus, psoriasis, or dermatitis herpetiformis. 
     
     
         10 . A method of packaging a skin treatment product for widespread consumer treatment, the method comprising:
 providing an oxygen-free packaging environment;   providing one or more product packages within the oxygen-free packing environment, the one or more product packages being substantially non-gas permeable;   within the oxygen-free packing environment, substantially filling the one or more product packages with a naringenin formulation; and   sealing the one or more product packages so as to be substantially non-gas permeable.   
     
     
         11 . The method of  claim 10 , wherein the one or more product package are consumer-sized packages. 
     
     
         12 . The method of  claim 10  further comprising providing a bulk product dispenser within the oxygen free packaging environment, the bulk product dispenser including a bulk portion of the naringenin formula for dispensing into the one or more product packages. 
     
     
         13 . The method of  claim 10 , wherein the naringenin formulation further comprises naringin. 
     
     
         14 . The method of  claim 10 , wherein the naringenin formulation does not include naringin. 
     
     
         15 . The method of  claim 10 , wherein the naringenin formulation is a water-based naringenin solution. 
     
     
         16 . A packaged treatment for treating a skin condition in a human patient, the packaged treatment comprising:
 a product package that is substantially non-gas permeable; and   a naringenin formulation disposed within the product package,   wherein the naringenin formula was disposed within the product package within an oxygen-free environment.   
     
     
         17 . The packaged treatment of  claim 16 , wherein the naringenin formulation further comprises naringin. 
     
     
         18 . The method of  claim 16 , wherein the naringenin formulation does not include naringin. 
     
     
         19 . The method of  claim 16 , wherein the naringenin formulation is a water-based naringenin solution. 
     
     
         20 . The method of  claim 16 , wherein the skin condition is one or more of Rosacea, Ichthyosis, Actinic Keratosis, dermatitis, pruritus, psoriasis, or dermatitis herpetiformis.

Join the waitlist — get patent alerts

Track US2025042587A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.